• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, September 22, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Nanodiscs deliver personalized cancer therapy to immune system

Bioengineer by Bioengineer
December 26, 2016
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

ANN ARBOR — Researchers at the University of Michigan have had initial success in mice using nanodiscs to deliver a customized therapeutic vaccine for the treatment of colon and melanoma cancer tumors.

"We are basically educating the immune system with these nanodiscs so that immune cells can attack cancer cells in a personalized manner," said James Moon, the John Gideon Searle assistant professor of pharmaceutical sciences and biomedical engineering.

Personalized immunotherapy is a fast-growing field of research in the fight against cancer.

The therapeutic cancer vaccine employs nanodiscs loaded with tumor neoantigens, which are unique mutations found in tumor cells. By generating T-cells that recognize these specific neoantigens, the technology targets cancer mutations and fights to eliminate cancer cells and prevent tumor growth.

Unlike preventive vaccinations, therapeutic cancer vaccines of this type are meant to kill established cancer cells.

"The idea is that these vaccine nanodiscs will trigger the immune system to fight the existing cancer cells in a personalized manner," Moon said.

The nanodisc technology was tested in mice with established melanoma and colon cancer tumors. After the vaccination, twenty-seven percent of T-cells in the blood of the mice in the study targeted the tumors.

When combined with immune checkpoint inhibitors, an existing technology that amplifies T-cell tumor-fighting responses, the nanodisc technology killed tumors within 10 days of treatment in the majority of the mice. After waiting 70 days, researchers then injected the same mice with the same tumor cells, and the tumors were rejected by the immune system and did not grow.

"This suggests the immune system 'remembered' the cancer cells for long-term immunity," said Rui Kuai, U-M doctoral student in pharmaceutical sciences and lead author of the study.

"The holy grail in cancer immunotherapy is to eradicate tumors and prevent future recurrence without systemic toxicity, and our studies have produced very promising results in mice," Moon said.

The technology is made of extremely small, synthetic high density lipoproteins measuring roughly 10 nanometers. By comparison, a human hair is 80,000 to 100,000 nanometers wide.

"It's a powerful vaccine technology that efficiently delivers vaccine components to the right cells in the right tissues. Better delivery translates to better T-cell responses and better efficacy," said study co-senior author Anna Schwendeman, U-M assistant professor of pharmacy.

The next step is to test the nanodisc technology in a larger group of larger animals, Moon said.

EVOQ Therapeutics, a new U-M spinoff biotech company, has been founded to translate these results to the clinic. Lukasz Ochyl, a doctoral student in pharmaceutical sciences, is also a co-author.

The study, "Designer vaccine nanodiscs for personalized cancer immunotherapy," is scheduled for advance online publication Dec. 26 on the Nature Materials website.

###

Media Contact

Laura Bailey
[email protected]
734-647-1848
@umich

http://www.umich.edu/

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Dual-Camera System Enhances Lower-Limb Kinematics in Osteoarthritis

September 22, 2025

Severe Obesity Linked to Lower Rates of Recommended Cancer Screenings

September 22, 2025

SwRI Leads IMAP Payload Development for Upcoming Mission to Map Heliosphere Boundary

September 22, 2025

Lipids Trigger Activation of LC3-Associated Phagocytosis: A Key Cellular Degradation Pathway

September 22, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    156 shares
    Share 62 Tweet 39
  • Physicists Develop Visible Time Crystal for the First Time

    69 shares
    Share 28 Tweet 17
  • Tailored Gene-Editing Technology Emerges as a Promising Treatment for Fatal Pediatric Diseases

    50 shares
    Share 20 Tweet 13
  • Scientists Achieve Ambient-Temperature Light-Induced Heterolytic Hydrogen Dissociation

    49 shares
    Share 20 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Dual-Camera System Enhances Lower-Limb Kinematics in Osteoarthritis

Severe Obesity Linked to Lower Rates of Recommended Cancer Screenings

SwRI Leads IMAP Payload Development for Upcoming Mission to Map Heliosphere Boundary

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.